References
- World Health Organization [webpage on the Internet]Leishmaniasis. Fact sheet2016 Available from: http://www.who.int/mediacentre/factsheets/fs375/en/Accessed October 11, 2016
- FrézardFDemicheliCRibeiroRRPentavalent antimonials: new perspectives for old drugsMolecules20091472317233619633606
- AlvarJVélezIDBernCLeishmaniasis worldwide and global estimates of its incidencePLoS One201275e35671 Kirk M, editor22693548
- MarsdenPDMucosal leishmaniasis (“spundia” Escomel, 1911)Trans R Soc Trop Med Hyg19868068598763037735
- World Health OrganizationAccelerating Work to Overcome the Global Impact of Neglected Tropical Diseases – A Roadmap for ImplementationGenevaWHO Press2012 Available from: http://whqlibdoc.who.int/hq/2012/WHO_HTM_NTD_2012.1_eng.pdfAccessed October 11, 2016
- BermanJDWaddellDHansonBDBiochemical mechanisms of the antileishmanial activity of sodium stibogluconateAntimicrob Agents Chemother19852769169202411217
- BermanJDHansonWLLovelaceJKActivity of purine analogs against Leishmania donovani in vivoAntimicrob Agents Chemother19873111111133566235
- WyllieSCunninghamMLFairlambAHDual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovaniJ Biol Chem200427938399253993215252045
- JeddiFPiarrouxRMaryCAntimony resistance in leishmania, focusing on experimental researchJ Trop Med20112011115
- MarsdenPDPentavalent antimonials: old drugs for new diseasesRev Soc Bras Med Trop1985183187198
- GutiérrezVSeabraABRegueraRMKhandareJCalderónMNew approaches from nanomedicine for treating leishmaniasisChem Soc Rev201645115216826487097
- PrasadPNIntroduction to Nanomedicine and NanobioengineeringHoboken, NJJohn Wiley & Sons Inc2012
- KaurIPKakkarVDeolPKYadavMSinghMSharmaIIssues and concerns in nanotech product development and its commercializationJ Control Release2014193516224933600
- CLINAMThe European Summit for Clinical Nanomedicine and Targeted Medicine. The Translation to Knowledge Based Medicine Available from: https://clinam.org/images/stories/pdf/conference2015.pdfAccessed October 11, 2016
- TripathySRoySA review of age-old antimalarial drug to combat malaria: efficacy up-gradation by nanotechnology based drug deliveryAsian Pac J Trop Med201479673679
- PrabhuPPatravaleVJoshiMNanocarriers for effective topical delivery of anti-infectivesCurr Nanosci201284491503
- Moosavian KalatSAKhamesipourABavarsadNUse of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c miceExp Parasitol2014143151024780938
- PhamTTHLoiseauPMBarrattGStrategies for the design of orally bioavailable antileishmanial treatmentsInt J Pharm2013454153955223871737
- GrafovAGrafovaIFrancoAMRLeskeläMLeishmanicidal inorgano-organic nanohybrids, synthesis and application of the samePatent BR10 2013 029618 0
- ColesGCBauerCBorgsteedeFHMWorld association for the advancement of veterinary parasitology (W.A.A.V.P.) methods for the detection of anthelmintic resistance in nematodes of veterinary importanceVet Parasitol1992441–235441441190
- AbeMItoTSynthetic inorganic ion-exchange materials. X. Preparation and properties of so-called antimonic(V) acidBull Chem Soc Jpn1968412333342
- BajārsGLagzdonsJPetrovskisGSolid proton electrolytes in electrochromic systemsLusisAElektrokhromizmRigaLatvian State University19875166
- NovikovBGMaterovaEABelinskayaFAOn the nature and stability of precipitated polyantimonic acidsRuss J Inorg Chem197520615661572
- DzimitrowiczDJGoodenoughJBWisemanPJA.C. proton conduction in hydrous oxidesMater Res Bull1982178971979
- VaivarsGJKleperisJJLūsisARStudy on antimonic acid hydrates obtained by sol methodRuss J Electrochem1992281014381443
- RobertsWLMcMurrayWJRaineyPMCharacterization of the antimonial antileishmanial agent meglumine antimonate (glucantime)Antimicrob Agents Chemother1998425107610829593130
- EbnerFHellerARippkeFTauschITopical use of dexpanthenol in skin disordersAm J Clin Dermatol20023642743312113650
- BissettDLOblongJEGoodmanLJTopical vitaminsDraelosZDCosmetic Dermatology: Products and Procedures2nd edWiley-Blackwell2015336345